- Home
- CNTA vs GPCR Comparison
CNTA vs GPCR Comparison
Compare CNTA & GPCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNTA
- GPCR
- Stock Information
- Founded
- CNTA 2020
- GPCR 2016
- Country
- CNTA United Kingdom
- GPCR United States
- Employees
- CNTA N/A
- GPCR N/A
- Industry
- CNTA Biotechnology: Pharmaceutical Preparations
- GPCR
- Sector
- CNTA Health Care
- GPCR
- Exchange
- CNTA Nasdaq
- GPCR Nasdaq
- Market Cap
- CNTA 2.2B
- GPCR 1.8B
- IPO Year
- CNTA 2021
- GPCR 2023
- Fundamental
- Price
- CNTA $17.91
- GPCR $33.15
- Analyst Decision
- CNTA Strong Buy
- GPCR Buy
- Analyst Count
- CNTA 7
- GPCR 5
- Target Price
- CNTA $23.71
- GPCR $86.80
- AVG Volume (30 Days)
- CNTA 680.3K
- GPCR 817.2K
- Earning Date
- CNTA 11-12-2024
- GPCR 11-13-2024
- Dividend Yield
- CNTA N/A
- GPCR N/A
- EPS Growth
- CNTA N/A
- GPCR N/A
- EPS
- CNTA N/A
- GPCR N/A
- Revenue
- CNTA $6,853,000.00
- GPCR N/A
- Revenue This Year
- CNTA N/A
- GPCR N/A
- Revenue Next Year
- CNTA N/A
- GPCR N/A
- P/E Ratio
- CNTA N/A
- GPCR N/A
- Revenue Growth
- CNTA N/A
- GPCR N/A
- 52 Week Low
- CNTA $5.58
- GPCR $26.61
- 52 Week High
- CNTA $18.74
- GPCR $66.38
- Technical
- Relative Strength Index (RSI)
- CNTA 59.93
- GPCR 41.20
- Support Level
- CNTA $16.43
- GPCR $29.60
- Resistance Level
- CNTA $18.33
- GPCR $35.31
- Average True Range (ATR)
- CNTA 1.25
- GPCR 2.66
- MACD
- CNTA 0.06
- GPCR -0.09
- Stochastic Oscillator
- CNTA 75.67
- GPCR 34.69
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include 1) SerpinPC for Hemophilia A, B, 2) LB101 for Solid Tumors, 3) ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders, 4) MGX292 Pulmonary Arterial Hypertension (PAH) and 5) Undisclosed for Solid Tumors.
About GPCR Structure Therapeutics Inc.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company aiming to develop and deliver novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small-molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073 and LTSE-2578.